Patents Assigned to Molecular Defenses Corporation
  • Patent number: 9901611
    Abstract: The use of glutathione to treat or prophylax viral, bacterial, chemical, and nuclear agents, or to treat or prophylax radiation injury to humans due to release of radioactive elements. The preferred formulation is an oral dosage form, with reduced glutathione stabilized by ascorbic acid, packaged to under controlled humidity and temperature conditions to ensure creation of charge transfer complexes that ensure consistent packaging, insignificant oxidation during packaging and subsequent normal storage, and high oral bioavailability for humans.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: February 27, 2018
    Assignee: Molecular Defenses Corporation
    Inventors: Harry B. Demopoulos, Kevin Davis